External factors such as diet and lifestyle may be important in the etiology of invasive prostate cancer. Specific features of prostate cancer, including high prevalence, long latency, and significant mortality and morbidity, provide the opportunities for chemoprevention.
Methods
The authors examine the experimental and epidemiological data demonstrating the chemopreventive activity, safety, and toxicity of chronic administration of these specific nutrients as chemopreventive agents in prostate cancer.
Results
Several nutrients have been identified as agents that inhibit mutagenesis and hyperproliferation or induce apoptosis or differentiation, which are critical characteristics for chemoprevention. Successful chemopreventive strategies require well-characterized agents, suitable cohorts, and reliable intermediate biomarkers of cancer for evaluating efficacy. Phytoestrogens/isoflavones, vitamins D and E, selenium, and lycopene have been identified as promising nutrients in the role of chemoprevention of prostate cancer.
Conclusions
Clinical studies to evaluate the safety and effectiveness of these agents as future prospects in cancer chemoprevention, both individually and in combination, are warranted.
References
1.
Cancer Facts & Figures, 1999.Atlanta, Ga: American Cancer Society; 1999.
2.
AdlercreutzH.. Western diet and Western diseases: some hormonal and biochemical mechanisms and associations.Scand J Clin Lab Invest.1990; 201: 3–23.
3.
SetchellK.D., BorrielloS.P., HulmeP.. Nonsteroidal estrogens of dietary origin: possible roles in hormone dependent disease.Am J Clin Nutr.1984; 40: 569–578.
4.
AdlercreutzH., MousaviY., ClarkJ.. Dietary phytoestrogens and cancer: in vitro and in vivo studies.J Steroid Biochem Mol Biol.1992; 41: 331–337.
5.
AdlercreutzH., GorbachS., GoldinB.. Diet and urinary estrogen profile in various populations: a preliminary report. Presented at the 14th International Meeting on Polycyclic Aromatic Hydrocarbons; 1993.
6.
AdlercreutzH., MazurW.. Phyto-estrogens and Western diseases.Ann Med.197;29: 95–120.
7.
CarlstromK., StegeR.. Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls.Br J Urol.1997; 79: 427–431.
8.
GannP.H., HennekensC.H., MaJ.. Prospective study of sex hormone levels and risk of prostate cancer.J Natl Cancer Inst.1996; 88: 1118–1126.
9.
NomuraA.M., KolonelL.N.. Prostate cancer: a current perspective.Epidemiol Rev.1991; 13: 200–227.
10.
KelloffG.J., LiebermanR., SteeleV.E.. Chemoprevention of prostate cancer: concepts and strategies.Eur Urol.1999; 35: 342–350.
KelloffG.J., HawkE.T., KarpJ.E.. Progress in clinical chemoprevention.Semin Oncol.1997; 24: 241–252.
13.
ReddyB.S.. Micronutrients as chemopreventive agents.IARC Sci Publ.1996; 139: 221–235.
14.
MessinaM., BarnesS.. The role of soy products in reducing risk of cancer.J Natl Cancer Inst.1991; 83: 541–546.
15.
AdlercruetzH., FotsisT., SchweigererL.. Isoflavonoids and 2-methoxyestradiol: inhibitors of tumor cell growth and angiogenesis.Proc Annu Meet Am Assoc Cancer Res.1994; 35: 693–694.
16.
AdlercreutzH., HöckerstedtK., BannwartC.. Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG).J Steroid Biochem.1987; 27: 1135–1144.
17.
FotsisT., PepperM., AdlercruetzH.. Genistein, a dietary-derived inhibitor of in-vitro angiogenesis.Proc Natl Acad Sci U S A.1993; 90: 2690–2694.
18.
FotsisT., PepperM., AdlercruetzH.. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis.J Nutr.1995; 125(3 suppl): 790S–797S.
19.
MolteniA., Brizio-MolteniL., PerskyV.. In vitro hormonal effects of soybean isoflavones.J Nutr.1995; 125(3 suppl): 751S–756S.
20.
WangT.T., SathyamoorthyN., PhangJ.M.. Differential effects of genistein on p52 expression and proliferation in MCF-7 cells are concentration-dependent.Proc Annu Meet AICR.1994; 35: A503.
21.
PagliacciM.C., SmacchiaM., MiglioratiG.. Growth-inhibitory effects of natural phyto-estrogen genistein in MCF-7 human breast cancer cells.Eur J Cancer.1994; 30A: 1675–1682.
22.
AdlercreutzH., HonjoH., HigashiA.. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet.Am J Clin Nutr.1991; 54: 1093–1100.
23.
BarnesS.. Effect of genistein on in vitro and in vivo models of cancer.J Nutr.1995; 125(3 suppl): 777S–783S.
24.
HempstockJ., KavanaghJ.P., GeorgeN.J.R.. Growth inhibitors of human prostatic cell lines by phytoestrogens. Proceedings from the 2nd International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. Belgium; 1996.
25.
SchleicherR., ZhengM., ZhangM.. Genistein inhibition in prostate cancer cell growth and metastasis in vivo. Proceedings from the 2nd International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. Belgium; 1996.
26.
AdlercreutzH., BannwartC., WähäläK.. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens.J Steroid Biochem Mol Biol.1993; 44: 147–153.
27.
NguyenM.L., SchwartzS.J.. Lycopene: chemical and biological properties.Food Technol.1999; 53: 38–45.
28.
GesterH.. The potential role of lycopene for human health.J Am Col Nutr.1997; 16: 109–126.
29.
StahlW., SeisH.. Lycopene: a biologically important carotenoid for humans?Arch Biochem Biophys.1996; 336: 1–9.
GiovannucciE.. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature.J Natl Cancer Inst.1999; 91: 317–331.
32.
GannP.H., MaJ., GiovannucciE.. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.Cancer Res.1999; 59: 1225–1230.
33.
RaoA.V., FleshnerN., AgarwalS.. Serum and tissue lycopene and biomarkers of oxidation in prostate cancer patients: a case-control study.Nutr Cancer.1999; 33: 159–164.
34.
KucukO., SakrW., SarkarF.H.. Lycopene supplementation in men with localized prostate cancer (PCa) modulates grade and volume of prostatic intraepithelial neoplasia (PIN) and tumor, level of serum PSA and biomarkers of cell growth, differentiation and apoptosis.Proc Annu Meet Am Assoc Cancer Res.1999; 40: 409. Abstract.
35.
MeydaniM.. Vitamin E.Lancet.1995; 345: 170–175.
36.
HsingA.W., ComstockG.W., AbbeyH.. Serologic precursors of cancer: retinol, carotenoids, and tocopherol and risk of prostate cancer.J Natl Cancer Inst.1990; 82: 941–946.
37.
HayesR.B., BogdanoviczJ.F., SchroederF.H.. Serum retinol and prostate cancer.Cancer.1988; 62: 2021–2026.
38.
ChanJ.M., StampferM.J., MaJ.. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States.Cancer Epidemiol Biomarkers Prev.1999; 8: 893–899.
39.
KristalA.R., StanfordJ.L., CohenJ.H.. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer.Cancer Epidemiol Biomarkers Prev.1999; 8: 887–892.
40.
ClarkL.C., CombsGFJr, TurnbullB.W.. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group.JAMA.1996; 276: 1957–1963.
41.
HeinonenO.P., AlbanesD., VirtamoJ.. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial.J Natl Cancer Inst.1998; 90: 440–446.
42.
FleshnerN., FairW.R., HurykR.. Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice.J Urol.1999; 161: 1651–1654.
43.
RippleM.O., HenryW.F., RagoR.P.. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells.J Natl Cancer Inst.1997; 89: 40–48.
44.
KnektP., AromaaA., MaatelaJ.. Serum selenium and subsequent risk of cancer among Finnish men and women.J Natl Cancer Inst.1990; 82: 864–868.
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group.N Engl J Med.1994; 330: 1029–1035.
47.
BendichA., MachlinL.J.. Safety of oral intake of vitamin E.Am J Clin Nutr.1988; 48: 612–619.
48.
CoatesR.J., WeissN.S., DalingJ.R.. Serum levels of selenium and retinol and the subsequent risk of cancer.Am J Epidemiol.1988; 128: 515–523.
49.
YoshizawaK., WillettW.C., MorrisS.J.. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer.J Natl Cancer Inst.1998; 90: 1219–1224.
50.
BluttS.E., WeigelN.L.. Vitamin D and prostate cancer.Proc Soc Exp Biol Med.1999; 221: 89–98.
51.
KonetyB.R., JohnsonC.S., TrumpD.L.. Vitamin D in the prevention and treatment of prostate cancer.Semin Urol Oncol.1999; 17: 77–84.
52.
GiovannucciE.. Dietary influences of 1,25(OH)2 vitamin D in relation to prostate cancer: a hypothesis.Cancer Causes Control.1998; 9: 567–582.
53.
CorderE.H., GuessH.A., HulkaB.S.. Vitamin D and prostate cancer: a prediagnostic study with stored sera.Cancer Epidemiol Biomarkers Prev.1993; 2: 467–472.
